For Research Purposes Only — 99%+ Purity Guaranteed — USA Sourced
Kisspeptin-10 is a synthetic decapeptide (Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂) corresponding to the active fragment of the KISS1 gene product. It binds to the GPR54 (KISS1R) receptor, activating Gq-mediated signaling cascades and modulating gonadotropin-releasing hormone (GnRH) expression in preclinical studies. Kisspeptin-10 serves as a tool for exploring reproductive and neuroendocrine peptide signaling.
For research use only. Not for human consumption.
References:
Kotani M et al., J Biol Chem, 2001 276(37):34631–34636
Oakley AE et al., Endocr Rev, 2009 30(6):713–743
de Roux N et al., N Engl J Med, 2003 349(17):1614–1627
In stock
This product is intended for laboratory research purposes only. Not for human consumption, veterinary, or medical use.
Kisspeptin peptides (also referenced as metastin; KISS1-derived ligands) are endogenous signaling molecules studied in vertebrate neuroendocrine biology and cellular signaling research. Kisspeptin-10 (Kp-10) is a short, C-terminal bioactive fragment frequently used in experimental systems to probe KISS1 receptor (KISS1R/GPR54) activation, downstream second-messenger signaling, and gene-regulatory responses across neuroendocrine and peripheral tissues.
In preclinical literature, kisspeptin signaling is commonly investigated for its role in hypothalamic GnRH neuron activation, pituitary gonadotropin secretion dynamics, metabolic signaling interfaces, vascular biology endpoints, and tumor cell migration/adhesion phenotypes in cell-based and animal models.
Sequence: YNWNSFGLRF
Molecular Formula: C63H83N17O14
Molecular Weight: 1302.4 g/mol
PubChem CID: 25240297
Synonyms: KISS-1, Protein KISS-1, metastin, Kp-10 peptide
Source: PubChem
Kisspeptin-10 is used in laboratory research to activate KISS1R and interrogate downstream signaling modules that couple receptor activation to intracellular calcium mobilization, kinase cascades, and transcriptional responses. In neuroendocrine-focused models, kisspeptin signaling is a common experimental handle for studying GnRH neuron excitability, pulsatile gonadotropin release patterns, and regulatory feedback logic within the hypothalamic-pituitary-gonadal axis as defined in nonclinical experimental settings [1] [2].
Experimental work evaluating kisspeptin ligands has characterized KISS1R-dependent activation of GnRH neuron signaling and associated changes in downstream gonadotropin secretion dynamics in controlled study designs [1] [2]. These models are frequently used to examine pulse generation, receptor desensitization, and axis-level response characteristics under defined stimulation paradigms.
Kisspeptin neurons are widely studied as integrators of metabolic state signals with neuroendocrine outputs. Preclinical genetics and receptor-localization studies have reported Kiss1r expression in adipose tissues and have used receptor loss-of-function approaches to evaluate changes in adiposity-related phenotypes and energy expenditure endpoints in animal models [3]. These findings support ongoing research into how KISS1R signaling intersects with metabolic pathways, peripheral tissue signaling, and neuroendocrine control circuitry.
KISS1/kisspeptin signaling has been investigated in oncology research primarily for its association with metastatic behavior and cell motility phenotypes. Published work has reported kisspeptin-linked modulation of tumor cell migration and related adhesion/invasion-associated processes in experimental models, with observations across multiple tumor contexts [4] [5]. These studies are often framed around pathway complexity, context-specific signaling, and heterogeneity of tumor biology across cell lines and model systems.
Source: ScienceDirect
Additional reports discuss potential coupling between kisspeptin signaling, circadian/light-cycle variables, and melatonin pathway markers in mouse-based experimental designs evaluating tumor growth endpoints [6]. These observations are typically used to motivate further mechanistic work on endocrine-circadian crosstalk and tumor microenvironment signaling.
Select studies have evaluated kisspeptin-related peptide analogs in rodent behavioral paradigms that measure spatial learning, navigation, and cognitive flexibility under defined experimental conditions [7]. Such work is generally used to probe neuromodulatory signaling hypotheses and to map peptide-receptor activity onto circuit-level function in nonclinical models.
Research has examined kisspeptin-associated modulation of limbic and reward-circuit activity using experimental brain processing readouts, supporting broader investigation into how neuroendocrine peptides interface with motivational circuitry and affective processing in controlled study designs [8].
Kisspeptin and KISS1R expression has been reported in renal tissue, and receptor-deficient mouse models have been used to study developmental and functional endpoints relevant to renal biology [9]. In cardiovascular research, kisspeptin signaling has been evaluated for context-specific effects in vascular beds, including experimental endpoints related to vasoreactivity and vascular signaling pathways, with emphasis on mechanistic interpretation and tissue-specific receptor biology [9].
Kisspeptin-10 is supplied as a synthetic research peptide for controlled laboratory workflows. Researchers commonly document identity using sequence and registry identifiers and may employ internal qualification workflows aligned with peptide characterization practices (e.g., chromatographic purity assessment and mass confirmation) consistent with laboratory standards.
Floriana Morgillo, M.D. is an Associate Professor of Medical Oncology at the University of Campania “Luigi Vanvitelli”. She received her Medical Degree, cum laude, in 2000 and in 2004 she completed her specialisation in Medical Oncology with Professor Fortunato Ciardiello at the Second University of Naples. In February 2008 she completed the PhD course in Medical Oncology at the same University. From February 2004 to February 2006, she worked at the MD Anderson Cancer Center in the Thoracic Head and Neck Medical Department. During this time she was deeply involved in the studies of acquired resistance to anti-EGFR targeted drugs in non-small cell lung cancer. In June 2009 she received a Translational Research fellowship from ESMO. She is the Principal Investigator and covers the role of Sub-Investigator in several clinical trials and has been a co-author in various publications in important international journals, including one study on the effects of Kisspeptin-10 antitumor efficacy. Floriana Morgillo, M.D. is listed in [10] under the referenced citations.
Floriana Morgillo, M.D. is being referenced as one of the leading scientists involved in the research and development of Kisspeptin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Floriana Morgillo is listed in [10] under the referenced citations.
W. S. Dhillo et al., “Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males,” J. Clin. Endocrinol. Metab., vol. 90, no. 12, pp. 6609–6615, Dec. 2005, doi: 10.1210/jc.2005-1468.
J. T. George et al., “Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men,” J. Clin. Endocrinol. Metab., vol. 96, no. 8, pp. E1228-1236, Aug. 2011, doi: 10.1210/jc.2011-0089.
C. J. L. Harter, G. S. Kavanagh, and J. T. Smith, “The role of kisspeptin neurons in reproduction and metabolism,” J. Endocrinol., vol. 238, no. 3, pp. R173–R183, 2018, doi: 10.1530/JOE-18-0108.
E. J. Mead, J. J. Maguire, R. E. Kuc, and A. P. Davenport, “Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system,” Br. J. Pharmacol., vol. 151, no. 8, pp. 1143–1153, Aug. 2007, doi: 10.1038/sj.bjp.0707295.
T. Ly, S. Harihar, and D. R. Welch, “KISS1 in metastatic cancer research and treatment: potential and paradoxes,” Cancer Metastasis Rev., Mar. 2020, doi: 10.1007/s10555-020-09868-9.
P. Pazarci et al., “The effects of daylight exposure on melatonin levels, Kiss1 expression, and melanoma formation in mice,” Croat. Med. J., vol. 61, no. 1, pp. 55–61, Feb. 2020.
E. Gibula-Tarlowska and J. H. Kotlinska, “Kissorphin improves spatial memory and cognitive flexibility impairment induced by ethanol treatment in the Barnes maze task in rats,” Behav. Pharmacol., vol. 31, no. 2 & 3, pp. 272–282, Apr. 2020, doi: 10.1097/FBP.0000000000000557.
A. N. Comninos et al., “Kisspeptin modulates sexual and emotional brain processing in humans,” J. Clin. Invest., vol. 127, no. 2, pp. 709–719, doi: 10.1172/JCI89519.
M. Bhattacharya and A. V. Babwah, “Kisspeptin: Beyond the Brain,” Endocrinology, vol. 156, no. 4, pp. 1218–1227, Apr. 2015, doi: 10.1210/en.2014-1915.
